Novartis resumes business in Ukraine after reviewing safety protocols amid war
seekingalpha.com
finance
2022-06-02 08:34:12

Jun. 02, 2022 4:34 AM ETNovartis AG (NVS)By: Ravikash, SA News Editor Robert Way/iStock Editorial via Getty Images Novartis (NYSE:NVS) is resuming business in Ukraine after reviewing safety protocols in the war-torn country. The Swiss pharma giant said that after studying current safety protocols in the country, and on advice which it will regularly review, it has begun to resume business operations remotely to help restore some basic critical business processes. Novartis said in a June 1 release that safety of its people remains its priority, and it would constantly review the situation and its business operations in Ukraine.
